Navigation Links
AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
Date:7/7/2009

among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Opertech Bio, Inc., a company that ... approach to sensory evaluation, today announced the issuance ... Patent and Trademark Office, encompassing high-throughput sensory discrimination ... taste evaluation technology called Microtiter Operant Gustometer or ... for rapid characterization of taste sensory properties,” said ...
(Date:9/2/2014)... - Oncothyreon Inc. (Nasdaq: ONTY ) announced today that ... will present at the Rodman & Renshaw 16 th ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... presentation will be accessible by visiting the Oncothyreon website ... About Oncothyreon Oncothyreon is a biotechnology ...
(Date:9/2/2014)... Mount, NC (PRWEB) September 02, 2014 ... establishment of its 11th clinical research site: PMG Research ... assumed ownership and operation of the clinical research department ... further expanding PMG’s presence in eastern North Carolina. This ... patients. For the patients in Rocky Mount and the ...
(Date:9/2/2014)... The inventors of tinAway, a novel ... are seeking support for development costs through a crowdfunding ... http://igg.me/at/tinaway ), was launched on September 1, 2014. , ... and is based on ten years of neuroscience ... and software engineers, Dr. Ian Dixon and Mr. Tony ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... QUEBEC CITY, Aug. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... on,endocrinology and oncology, today reported financial and operating results,for the ... Highlights, - Advancement of cetrorelix Phase 3 program ... trial: patient enrollment completed; - ...
... ST. LOUIS, Aug. 12 At the Board ... quarterly cash dividend of,$.13 per share. The dividend ... record on September 2, 2008., About Sigma-Aldrich: ... company. Our biochemical and organic chemical products and ...
... LI-COR Biosciences continues to,expand its offering of ... new IRDye(R) 680 Donkey Anti-Chicken IgG, IRDye ... IgG, and IRDye 800CW Goat,Anti-Rat IgG antibodies ... detection for multiple applications including,quantitative Westerns, In-Cell ...
Cached Biology Technology:AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 7
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
(Date:8/29/2014)... news release is available in German . ... key players in the natural nitrogen cycle on Earth ... specialist bacteria were thought to depend on nitrite as ... led by Holger Daims, a microbiologist at the University ... use hydrogen as an alternative source of energy. The ...
(Date:8/29/2014)... such as the prolific bloomer Emiliania huxleyi , ... discovered. The finding contradicts the common view that ... on scarce supplies of thiamine in the ocean to ... about the ocean," says CIFAR Senior Fellow Alexandra ... paper with CIFAR fellows John Archibald (Dalhousie ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... fittest survive has been called into question by new research ... A collaboration between the Universities of Exeter and Bath in ... in the US, challenges our current understanding of evolution by ... The work represents a new approach to studying evolution that ...
... done by Mark Lusk and colleagues at the Colorado ... solar cells. Their latest work describes how the size ... energy to electrons to generate electricity. The results ... ACS Nano . The advance provides evidence ...
... NeoProteomics Inc., a biomarker development and software ... Case Western Reserve University. The deal has potential ... diabetes, and inflammatory diseases. Proteomics is the ... structures of biological systems. NeoProteomics, founded in 2006 ...
Cached Biology News:Research shows not only the fittest survive 2Size matters: Smaller particles could make solar panels more efficient 2Case Western Reserve and NeoProteomics announce exclusive option 2
...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
...
Request Info...
Biology Products: